Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 3/20 | 1.00 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.80 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.80 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | VDR | P11473 | 1/20 | 0.78 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycoursodeoxycholic Acid SCHEMBL20204267 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL13851608 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL11962429 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL28793575 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL9151495 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL12917601 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycochenodeoxycholate SCHEMBL236354 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL59881 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL935341 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 | |
| Glycoursodeoxycholic Acid SCHEMBL10694925 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11ENPP2SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146298-A1 | INTESTINAL BIOMARKERS FOR GUT HEALTH IN DOMESTICATED BIRDS | INTERNATIONAL N&H DENMARK APS (DK) | 2026-05-28 | — | — | US | claimed |
| US-20260146992-A1 | INTESTINAL BIOMARKERS FOR GUT HEALTH IN DOMESTICATED BIRDS | INTERNATIONAL N&H DENMARK APS (DK) | 2026-05-28 | — | — | US | claimed |
| CN-122075501-A | Application of tauroursodeoxycholic acid in inhibiting alpha-glucosidase activity | — | 2026-05-26 | — | — | CN | claimed |
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| CN-122017247-A | Plasma metabolism marker for distinguishing benign thyroid diseases from early thyroid cancers and application of plasma metabolism marker | 哈尔滨脉图精准技术有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122017068-A | Bile acid high-flux detection method based on ultra-high performance liquid chromatography tandem mass spectrometry and application thereof | 青岛百谱生物科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4721745-A1 | COMBINED PRODUCT, SALT AND USE THEREOF | Shanghai Henlius Biotech, Inc. (CN) | 2026-04-08 | — | — | EP | claimed |
| EP-4721740-A1 | COMBINATION PRODUCT, SALT, AND USE THEREOF IN TREATING NEURODEGENERATIVE DISEASES OR DISORDERS | Shanghai Henlius Biotech, Inc. (CN) | 2026-04-08 | — | — | EP | claimed |
| US-20260076959-A1 | COMBINATION PRODUCT, SALT, AND USE THEREOF IN TREATING NEURODEGENERATIVE DISEASES OR DISORDERS | SHANGHAI HENLIUS BIOTECH INC (CN) | 2026-03-19 | — | — | US | claimed |
| US-20260078118-A1 | COMBINED PRODUCT, SALT AND USE THEREOF | SHANGHAI HENLIUS BIOTECH INC (CN) | 2026-03-19 | — | — | US | claimed |
| US-6251428-B1 | ADJUVANT, CARRIER | YOO SEO HONG (US) | 2001-06-26 | — | — | US | claimed |
| WO-2001012155-A1 | COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2001-02-22 | — | — | WO | claimed |
| WO-2001009163-A2 | IMPROVEMENT OF PEPTIDE TRANSPORT BY CONJUGATION WITH BILE ACIDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2001-02-08 | — | — | WO | claimed |
| WO-2001001960-A1 | CLEAR OIL-CONTAINING PHARMACEUTICAL COMPOSITIONS | LIPOCINE, INC. (US) | 2001-01-11 | — | — | WO | claimed |
| WO-2000050007-A1 | COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF HYDROPHOBIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2000-08-31 | — | — | WO | claimed |
| WO-2000004875-A2 | PREPARATION OF AQUEOUS CLEAR SOLUTION DOSAGE FORMS WITH BILE ACIDS | YOO SEO HONG (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0910411-A1 | HYDROPHOBIC PREPARATIONS CONTAINING MEDIUM CHAIN MONOGLYCERIDES | Cortecs (UK) Limited (GB) | 1999-04-28 | — | — | EP | claimed |
| WO-1998000169-A1 | HYDROPHOBIC PREPARATIONS CONTAINING MEDIUM CHAIN MONOGLYCERIDES | CORTECS (UK) LIMITED) (GB) | 1998-01-08 | — | — | WO | claimed |
| US-5616741-A | Process for the preparation of glycine-conjugated bile acids | ERREGIERRE INDUSTRIA CHIMICA S.P.A. (IT) | 1997-04-01 | — | — | US | claimed |
| EP-0583566-A2 | Process for the preparation of glycine-conjugated bile acids and relative pharmaceutical compositions useful for treating hepatic insufficiency | ERREGIERRE INDUSTRIA CHIMICA Spa (IT) | 1994-02-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146992-A1 | INTESTINAL BIOMARKERS FOR GUT HEALTH IN DOMESTICATED BIRDS | FABP2, AADAT, HNMT | GPBAR1 105/4885NR1H4 1103/4885ABCB11 1527/4885 |
| US-20260076959-A1 | COMBINATION PRODUCT, SALT, AND USE THEREOF IN TREATING NEURODEGENERATIVE DISEASES OR DISORDERS | SLC10A1, CYP46A1, CYP27A1 | GPBAR1 4/4885NR1H4 6/4885ABCB11 22/4885 |
| US-20260078118-A1 | COMBINED PRODUCT, SALT AND USE THEREOF | SLC10A1, SLC10A2, CYP27A1 | GPBAR1 6/4885NR1H4 8/4885ABCB11 9/4885 |
| US-20260146298-A1 | INTESTINAL BIOMARKERS FOR GUT HEALTH IN DOMESTICATED BIRDS | FABP2, SI, CSTB | GPBAR1 2541/4885NR1H4 770/4885ABCB11 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.